Fyarro 100 mg lyophilized powder for injectable suspension Images
Generic Name: sirolimus protein-bound
This medication has been identified as Fyarro 100 mg lyophilized powder for injectable suspension. It is supplied by Aadi Bioscience.
Fyarro is used in the treatment of Malignant Perivascular Epithelioid Cell Tumor and belongs to the drug class mTOR inhibitors. Fyarro 100 mg lyophilized powder for injectable suspension is not a controlled substance under the Controlled Substances Act (CSA).
Images of medication
Fyarro
- Generic Name
- sirolimus protein-bound
- Strength
- 100 mg lyophilized powder for injectable suspension
- Availability
- Prescription only
- Drug Class
- MTOR inhibitors
- CSA Schedule
- Not a controlled drug
- Labeler / Supplier
- Aadi Bioscience
- National Drug Code (NDC)
- 80803-0153
More about Fyarro (sirolimus protein-bound)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Drug images
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: mTOR inhibitors
- En español
Patient resources
Professional resources
Related treatment guides
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.